Drug Profile
Research programme: small molecule therapeutics - HitGen/LEO Pharma
Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator HitGen
- Developer HitGen; LEO Pharma
- Class Skin disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for research development in Skin-disorders in China
- 12 Nov 2019 LEO Pharma and HitGen expands their collaboration with a license to develop a novel class of drugs for a dermatology indication
- 07 Aug 2017 Early research in Skin disorders in China (unspecified route)